Anthony Hoovler
Anthony Hoovler has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jamie E. Coborn
Novo Nordisk, Inc., Plainsboro, New Jersey, USA
2 shared publications - Katherine Sherif
Sidney Kimmel College of Medicine, Thomas Jefferson University
2 shared publications - Lisa Gill
Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Minnesota, USA
2 shared publications Abdalla Aly
Department of Clinical Data Science and Evidence, Novo Nordisk Inc
1 shared publicationAnran Tan
Department of Epidemiology, Genesis Research Group
1 shared publicationBrenna L. Brady
Merative
1 shared publication
Latest Publications
- Open Access
- 20 February 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 498-515
The healthcare resource utilization and costs associated with metabolic dysfunction-associated steatohepatitis among Medicare beneficiaries: a retrospective cohort study
The main objective of this study was to estimate the incremental healthcare resource utilization (HCRU) and costs attributable to metabolic dysfunction-associated steatohepatitis (MASH) from a Medicare fee-for-service perspective by comparing beneficiaries diagnosed with MASH with those not diagnosed with MASH. This observational study used 100% Medicare fee-for-service claims data from January 1, 2016, through December 31, 2022. The study population was stratified in cohorts based on MASH status. In the main analysis, the MASH cohort included all beneficiaries diagnosed with MASH, while the non-MASH cohort comprised a random sample of beneficiaries without a MASH diagnosis, matched in size to the MASH cohort. To compare the 2 cohorts, stabilized inverse probability of treatment weighting (IPTW) was used to adjust for differences in baseline covariates, including selected cardiometabolic conditions. Reported outcomes included all-cause, cardiovascular-related, and liver-related HCRU and costs after IPTW. The study included 128 622 beneficiaries in the MASH cohort and 128 579 beneficiaries in the non-MASH cohort. After IPTW, MASH was associated with higher all-cause HCRU rates, particularly for inpatient hospitalizations (rate ratio, 1.36; 95% CI, 1.33-1.39). This increase appeared to be driven by liver-related hospitalizations (rate ratio, 10.41; 95% CI, 9.40-11.42). Consistent with HCRU findings, mean total cost per patient per year was higher for MASH compared with non-MASH ($27 816 vs $25 666; mean cost difference, $2150; 95% CI, $1673-$2627). The HCRU and cost attributed to MASH could be underestimated because of MASH underdiagnosis and underreporting, as well as potential overadjustment for MASH-driven comorbidities in the IPTW model. Among Medicare fee-for-service beneficiaries aged 66 years and older, MASH was associated with significantly greater HCRU and costs, even after adjustment for cardiometabolic and other comorbidities. The higher HCRU and costs are likely driven by the management of liver disease, which may include cirrhosis and hepatic decompensation.
- 20 February 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 498-515
Open AccessThe healthcare resource utilization and costs associated with metabolic dysfunction-associated steatohepatitis among Medicare beneficiaries: a retrospective cohort study
The main objective of this study was to estimate the incremental healthcare resource utilization (HCRU) and costs attributable to metabolic dysfunction-associated steatohepatitis (MASH) from a Medicare fee-for-service perspective by comparing beneficiaries diagnosed with MASH with those not diagnosed with MASH. This observational study used 100% Medicare fee-for-service claims data from January 1, 2016, through December 31, 2022. The study population was stratified in cohorts based on MASH status. In the main analysis, the MASH cohort included all beneficiaries diagnosed with MASH, while the non-MASH cohort comprised a random sample of beneficiaries without a MASH diagnosis, matched in size to the MASH cohort. To compare the 2 cohorts, stabilized inverse probability of treatment weighting (IPTW) was used to adjust for differences in baseline covariates, including selected cardiometabolic conditions. Reported outcomes included all-cause, cardiovascular-related, and liver-related HCRU and costs after IPTW. The study included 128 622 beneficiaries in the MASH cohort and 128 579 beneficiaries in the non-MASH cohort. After IPTW, MASH was associated with higher all-cause HCRU rates, particularly for inpatient hospitalizations (rate ratio, 1.36; 95% CI, 1.33-1.39). This increase appeared to be driven by liver-related hospitalizations (rate ratio, 10.41; 95% CI, 9.40-11.42). Consistent with HCRU findings, mean total cost per patient per year was higher for MASH compared with non-MASH ($27 816 vs $25 666; mean cost difference, $2150; 95% CI, $1673-$2627). The HCRU and cost attributed to MASH could be underestimated because of MASH underdiagnosis and underreporting, as well as potential overadjustment for MASH-driven comorbidities in the IPTW model. Among Medicare fee-for-service beneficiaries aged 66 years and older, MASH was associated with significantly greater HCRU and costs, even after adjustment for cardiometabolic and other comorbidities. The higher HCRU and costs are likely driven by the management of liver disease, which may include cirrhosis and hepatic decompensation.
- Open Access
- 28 February 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 314-322
Noninvasive tests and diagnostic pathways to MASH diagnosis in the United States: a retrospective observational study
Although liver biopsy is considered the most reliable diagnostic tool for metabolic dysfunction-associated steatohepatitis (MASH), it is invasive and can be costly. Clinicians are increasingly relying on routine biomarkers and other noninvasive tests (NITs) for diagnosis. We examined real-world diagnostic pathways for patients newly diagnosed with MASH with a primary focus on NITs. This retrospective, observational study analyzed healthcare claims data (Merative MarketScan Commercial and Medicare Databases) from patients in the United States newly diagnosed with MASH from October 1, 2016, to March 31, 2023. Patients ≥18 years old with ≥12 months of continuous enrollment with medical and pharmacy benefits prior to diagnosis were included. Diagnostic pathways leading up to MASH diagnosis, including NITs (blood-based and imaging-based tests) and liver biopsies were assessed. Prevalence of comorbid conditions, MASH-associated medication use, and the diagnosing physician specialty were also examined. A total of 18,396 patients were included in the analysis. Routine laboratory tests (alanine aminotransferase [ALT], albumin, aspartate aminotransferase [AST], cholesterol, complete blood count, and hemoglobin A1c) were performed among ≥70% of patients prior to MASH diagnosis, including 89% of patients with a liver enzyme test (ALT and/or AST). More than 75% of patients had necessary laboratory tests to calculate AST to platelet ratio index (APRI) and fibrosis-4 index (FIB-4) scores. The most common imaging performed was ultrasound (62%); liver biopsy was only performed in 10% of patients. There was a high prevalence of cardiometabolic risk factors such as hyperlipidemia (66%), hypertension (62%), obesity (58%), type 2 diabetes (40%), and cardiovascular disease (21%). Nearly half of the patients (49%) were diagnosed by a primary care physician. This study highlights real-world diagnostic pathways among patients newly diagnosed with MASH, supporting previous findings that liver biopsies are infrequently used in favor of noninvasive methods.
- 28 February 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 314-322
Open AccessNoninvasive tests and diagnostic pathways to MASH diagnosis in the United States: a retrospective observational study
Although liver biopsy is considered the most reliable diagnostic tool for metabolic dysfunction-associated steatohepatitis (MASH), it is invasive and can be costly. Clinicians are increasingly relying on routine biomarkers and other noninvasive tests (NITs) for diagnosis. We examined real-world diagnostic pathways for patients newly diagnosed with MASH with a primary focus on NITs. This retrospective, observational study analyzed healthcare claims data (Merative MarketScan Commercial and Medicare Databases) from patients in the United States newly diagnosed with MASH from October 1, 2016, to March 31, 2023. Patients ≥18 years old with ≥12 months of continuous enrollment with medical and pharmacy benefits prior to diagnosis were included. Diagnostic pathways leading up to MASH diagnosis, including NITs (blood-based and imaging-based tests) and liver biopsies were assessed. Prevalence of comorbid conditions, MASH-associated medication use, and the diagnosing physician specialty were also examined. A total of 18,396 patients were included in the analysis. Routine laboratory tests (alanine aminotransferase [ALT], albumin, aspartate aminotransferase [AST], cholesterol, complete blood count, and hemoglobin A1c) were performed among ≥70% of patients prior to MASH diagnosis, including 89% of patients with a liver enzyme test (ALT and/or AST). More than 75% of patients had necessary laboratory tests to calculate AST to platelet ratio index (APRI) and fibrosis-4 index (FIB-4) scores. The most common imaging performed was ultrasound (62%); liver biopsy was only performed in 10% of patients. There was a high prevalence of cardiometabolic risk factors such as hyperlipidemia (66%), hypertension (62%), obesity (58%), type 2 diabetes (40%), and cardiovascular disease (21%). Nearly half of the patients (49%) were diagnosed by a primary care physician. This study highlights real-world diagnostic pathways among patients newly diagnosed with MASH, supporting previous findings that liver biopsies are infrequently used in favor of noninvasive methods.
- Open Access
- 6 June 2023
- Published by SAGE Publications in Journal of Women's Health
- Vol. 32 (6) , 723-731
Polycystic Ovary Syndrome and Obesity: A Cross-Sectional Survey of Patients and Obstetricians/Gynecologists
Background: Polycystic ovary syndrome (PCOS) is an endocrine disorder commonly affecting women of reproductive age. Compared with women without PCOS, women with PCOS are more likely to have overweight or obesity. Materials and Methods: To better understand the role of obstetricians/gynecologists (OB/GYNs) in diagnosis and treatment of patients with PCOS and obesity, we conducted an anonymous, United States population-based, cross-sectional online survey with 251 patients with PCOS and obesity and 305 health care professionals (HCPs), of which 125 were OB/GYNs. Results: In the most common patient journey, most patients were diagnosed (66%) and treated (59%) by OB/GYNs. Most patients (51%) considered OB/GYNs to be the coordinator of their PCOS care. For ongoing management of patients with PCOS and obesity, OB/GYNs reported prescribing general improvements in lifestyle (91%), oral contraceptives (91%), metformin (85%), letrozole (74%), spironolactone (71%), specific diets (60%), medroxyprogesterone (45%), and anti-obesity medications (27%). OB/GYNs were significantly more likely than other HCPs surveyed to strongly agree with the statement that they do not know enough about anti-obesity medications to feel comfortable prescribing them to their patients with PCOS and obesity ( p < 0.05). Most OB/GYNs believed that consultation with a dietitian/nutritionist (75%) or access to a physician who specializes in obesity (67%) were the most beneficial types of support for their patients with PCOS and obesity. Conclusions: OB/GYNs recognize the importance of obesity management for the treatment of PCOS; however, utilization of effective obesity tools to treat these patients is low. OB/GYNs may benefit from additional education on obesity management strategies.
- 6 June 2023
- Published by SAGE Publications in Journal of Women's Health
- Vol. 32 (6) , 723-731
Open AccessPolycystic Ovary Syndrome and Obesity: A Cross-Sectional Survey of Patients and Obstetricians/Gynecologists
Background: Polycystic ovary syndrome (PCOS) is an endocrine disorder commonly affecting women of reproductive age. Compared with women without PCOS, women with PCOS are more likely to have overweight or obesity. Materials and Methods: To better understand the role of obstetricians/gynecologists (OB/GYNs) in diagnosis and treatment of patients with PCOS and obesity, we conducted an anonymous, United States population-based, cross-sectional online survey with 251 patients with PCOS and obesity and 305 health care professionals (HCPs), of which 125 were OB/GYNs. Results: In the most common patient journey, most patients were diagnosed (66%) and treated (59%) by OB/GYNs. Most patients (51%) considered OB/GYNs to be the coordinator of their PCOS care. For ongoing management of patients with PCOS and obesity, OB/GYNs reported prescribing general improvements in lifestyle (91%), oral contraceptives (91%), metformin (85%), letrozole (74%), spironolactone (71%), specific diets (60%), medroxyprogesterone (45%), and anti-obesity medications (27%). OB/GYNs were significantly more likely than other HCPs surveyed to strongly agree with the statement that they do not know enough about anti-obesity medications to feel comfortable prescribing them to their patients with PCOS and obesity ( p < 0.05). Most OB/GYNs believed that consultation with a dietitian/nutritionist (75%) or access to a physician who specializes in obesity (67%) were the most beneficial types of support for their patients with PCOS and obesity. Conclusions: OB/GYNs recognize the importance of obesity management for the treatment of PCOS; however, utilization of effective obesity tools to treat these patients is low. OB/GYNs may benefit from additional education on obesity management strategies.
- Open Access
- 12 November 2022
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 135 (3) , 312-320
Medical journey of patients with polycystic ovary syndrome and obesity: a cross-sectional survey of patients and primary care physicians
Patients with polycystic ovary syndrome (PCOS) report dissatisfaction with the diagnostic process and are more likely to have overweight or obesity. We wanted to understand the role that primary care physicians (PCPs) play in the diagnosis of PCOS and how they contribute to treatment of patients with PCOS and obesity. A cross-sectional online survey was completed by 251 patients with PCOS and obesity (BMI ≥30 kg/m2) and 305 healthcare providers (PCPs, obstetricians/gynecologists, reproductive and general endocrinologists). This paper focuses on the 75 PCPs treating patients with PCOS and obesity. In the most common patient journey, we found that most patients with PCOS and obesity (53%) have initial discussions about PCOS symptoms with PCPs. However, less than one quarter of patients receive a PCOS diagnosis (22%) or initial treatment (24%) for PCOS from a PCP. One quarter of patients also reported receiving a misdiagnosis from a PCP prior to their PCOS diagnosis. Compared to other healthcare providers surveyed, PCPs were the least comfortable making a PCOS diagnosis. Compared to PCPs without an obesity management focus, PCPs with an obesity management focus were more likely to diagnose patients themselves (38% vs 62%) and initiate PCOS treatment themselves (42% vs 57%). According to PCPs, difficulty with obesity management (47%) was the top reason that patients with PCOS and obesity stop seeing them for PCOS management. PCPs are often the initial medical touchpoint for patients with PCOS and obesity. However, PCPs play a smaller role in diagnosis and treatment of PCOS. Increasing education on obesity management may encourage PCPs to diagnose and treat more patients with PCOS and offer strategies to help patients with obesity management.
- 12 November 2022
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 135 (3) , 312-320
Open AccessMedical journey of patients with polycystic ovary syndrome and obesity: a cross-sectional survey of patients and primary care physicians
Patients with polycystic ovary syndrome (PCOS) report dissatisfaction with the diagnostic process and are more likely to have overweight or obesity. We wanted to understand the role that primary care physicians (PCPs) play in the diagnosis of PCOS and how they contribute to treatment of patients with PCOS and obesity. A cross-sectional online survey was completed by 251 patients with PCOS and obesity (BMI ≥30 kg/m2) and 305 healthcare providers (PCPs, obstetricians/gynecologists, reproductive and general endocrinologists). This paper focuses on the 75 PCPs treating patients with PCOS and obesity. In the most common patient journey, we found that most patients with PCOS and obesity (53%) have initial discussions about PCOS symptoms with PCPs. However, less than one quarter of patients receive a PCOS diagnosis (22%) or initial treatment (24%) for PCOS from a PCP. One quarter of patients also reported receiving a misdiagnosis from a PCP prior to their PCOS diagnosis. Compared to other healthcare providers surveyed, PCPs were the least comfortable making a PCOS diagnosis. Compared to PCPs without an obesity management focus, PCPs with an obesity management focus were more likely to diagnose patients themselves (38% vs 62%) and initiate PCOS treatment themselves (42% vs 57%). According to PCPs, difficulty with obesity management (47%) was the top reason that patients with PCOS and obesity stop seeing them for PCOS management. PCPs are often the initial medical touchpoint for patients with PCOS and obesity. However, PCPs play a smaller role in diagnosis and treatment of PCOS. Increasing education on obesity management may encourage PCPs to diagnose and treat more patients with PCOS and offer strategies to help patients with obesity management.